Antibody-Drug Conjugate Shows Striking First-Line Results in HER2-Driven Lung Cancer
A multicenter real-world study found that first-line trastuzumab deruxtecan doubled progression-free survival compared with chemotherapy in HER2-altered advanced NSCLC, while ...
